Yasuharu Kunishima

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE Our aim was to prospectively analyze the 3-year outcomes of naftopidil treatment for patients with benign prostatic hyperplasia (BPH), including those who dropped out during follow-up and had retreatment for BPH after termination of the drug within 3 years. PATIENTS AND METHODS Naftopidil, 50 mg/d or 75 mg/d, was given to 117 patients having BPH(More)
  • 1